201 related articles for article (PubMed ID: 38733817)
21. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract][Full Text] [Related]
22. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
[TBL] [Abstract][Full Text] [Related]
23. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Feinberg D; Paul B; Kang Y
Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
[TBL] [Abstract][Full Text] [Related]
24. A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma.
Puertas B; Fernández-Sánchez A; Alejo E; Rey-Búa B; Martín-López AA; Pérez-López E; López-Parra M; López-Corral L; Gutiérrez-Gutiérrez NC; García-Sanz R; Puig N; González-Calle V; Mateos MV
Blood Adv; 2024 Jul; 8(13):3478-3487. PubMed ID: 38717869
[TBL] [Abstract][Full Text] [Related]
25. New and emerging pharmacotherapies for the management of multiple myeloma.
Moore DC; Oxencis CJ; Shank BR
Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
[TBL] [Abstract][Full Text] [Related]
26. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
[TBL] [Abstract][Full Text] [Related]
28. Targeting GPRC5D in multiple myeloma.
Elemian S; Al Hadidi S
Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
30. [Future therapeutic strategies for multiple myeloma].
Ishida T
Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
[TBL] [Abstract][Full Text] [Related]
31. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
[TBL] [Abstract][Full Text] [Related]
32. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
[TBL] [Abstract][Full Text] [Related]
33. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
34. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
35. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
37. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
38. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
40. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]